Qrons Inc
First Person Ltd., through its subsidiaries, engages in the formulation and distribution of wholesale food grade functional mushrooms and cognitive performance products focusing on the mental performance and wellness markets in the United States. It focuses on the research and development of psilocybin mushrooms. The company is headquartered in Calgary, Canada.
Qrons Inc (QRON) - Net Assets
Latest net assets as of December 2024: $-444.85K USD
Based on the latest financial reports, Qrons Inc (QRON) has net assets worth $-444.85K USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($659.00) and total liabilities ($445.51K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-444.85K |
| % of Total Assets | -67503.49% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 409.45 |
Qrons Inc - Net Assets Trend (2016–2024)
This chart illustrates how Qrons Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Qrons Inc (2016–2024)
The table below shows the annual net assets of Qrons Inc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-444.85K | +70.11% |
| 2023-12-31 | $-1.49 Million | -16.34% |
| 2022-12-31 | $-1.28 Million | -16.01% |
| 2021-12-31 | $-1.10 Million | -58.82% |
| 2020-12-31 | $-694.32K | -36.64% |
| 2019-12-31 | $-508.12K | -573.66% |
| 2018-12-31 | $107.28K | +429.15% |
| 2017-12-31 | $20.27K | -86.61% |
| 2016-12-31 | $151.37K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Qrons Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1021114800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $9.94 Million | % |
| Total Equity | $-444.85K | 100.00% |
Qrons Inc Competitors by Market Cap
The table below lists competitors of Qrons Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ATHENE HOLDING PRF.SER.C
F:ATR0
|
$199.81K |
|
CATALYST PHARMA (CN2.SG)
STU:CN2
|
$199.82K |
|
MARINE HARVEST
BE:PND
|
$199.87K |
|
MOBISTAR - Dusseldorf Stock Exchang
DU:MOS
|
$199.97K |
|
Madoro Metals Corp
PINK:MSTXF
|
$199.54K |
|
Indel B SpA
STU:2I6
|
$199.51K |
|
TRYG (TRYGVESTA) AS ORD
STU:T2V1
|
$199.38K |
|
FZDB11
SA:FZDB11
|
$199.29K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Qrons Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -1,488,293 to -444,848, a change of 1,043,445.
- Net loss of 56,097 reduced equity.
- Other factors increased equity by 1,099,542.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-56.10K | -12.61% |
| Other Changes | $1.10 Million | +247.17% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Qrons Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.00 | $0.15 | x |
| 2018-12-31 | $0.01 | $0.15 | x |
| 2019-12-31 | $-0.04 | $0.15 | x |
| 2020-12-31 | $-0.05 | $0.15 | x |
| 2021-12-31 | $-0.08 | $0.15 | x |
| 2022-12-31 | $-0.10 | $0.15 | x |
| 2023-12-31 | $-0.11 | $0.15 | x |
| 2024-12-31 | $-0.03 | $0.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Qrons Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-1199.73%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -111.80% | 0.00% | 0.00x | 1.03x | $-184.38K |
| 2017 | -7021.36% | 0.00% | 0.00x | 3.63x | $-1.43 Million |
| 2018 | -3664.44% | 0.00% | 0.00x | 1.83x | $-3.94 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.50 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-593.53K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-957.71K |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-605.59K |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-640.52K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.61K |
Industry Comparison
This section compares Qrons Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Qrons Inc (QRON) | $-444.85K | -111.80% | N/A | $199.80K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |